ProCE Banner Activity

Mini-HyperCVD + Inotuzumab Ozogamicin ± Blinatumomab in Older Adults With Newly Diagnosed Ph-Negative B-Cell ALL: Updated Phase II Results

Slideset Download
Conference Coverage
Among older adults newly diagnosed with Ph-negative B-cell ALL, mini-hyperCVD plus inotuzumab with or without blinatumomab was associated with a 5-year OS rate of 47%.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab